[Research Advance on Promoting Angiogenesis of Mesenchymal Stem Cells-Review].

Zhongguo Shi Yan Xue Ye Xue Za Zhi

Department of Experimental Hematology, Institute of Radiation Medicine, Military Medical Academy of PLA, Beijing 100850, China. E-mail:

Published: August 2017


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Mesenchymal stem cells (MSC) possess important biological characteristics of tissue repair and regeneration. MSC exert the properties promoting endogenous angiogenesis and have been widely applied in treatment of ischemia diseases. The therapeutic potency of MSC for ischemia diseases is owing to their secretion of angiogenic growth factors and release of exosomes. MSC promote angiogenesis stronger in hypoxia environment, and their miRNA played an important role in mediating regulation. This review summarizes recent advances in treatment of angiogenesis using MSC and their mechanisms. The angiogenic activities of MSC under hypoxia condition and their regulation by a miRNA network were discussed.

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2017.04.056DOI Listing

Publication Analysis

Top Keywords

mesenchymal stem
8
ischemia diseases
8
msc
6
[research advance
4
advance promoting
4
angiogenesis
4
promoting angiogenesis
4
angiogenesis mesenchymal
4
stem cells-review]
4
cells-review] mesenchymal
4

Similar Publications

Tumor necrosis factor-alpha (TNF-α) is a cytokine involved in the immune-inflammatory response. It can induce an odontoblastic phenotype and enhance biomineralization in dental pulp mesenchymal stem cells but does not have the same effect on osteoblasts. The reasons for this differential response, despite the shared lineage of these cell types, are not yet clear.

View Article and Find Full Text PDF

Crosstalk between leukemic cells and their surrounding mesenchymal stromal cells (MSCs) in the bone marrow microenvironment is crucial for the pathogenesis of myelodysplastic syndromes (MDS) and is mediated by extracellular vesicles (EVs). The EV-specific miRNAs derived from MDS-MSCs remain poorly explored. EVs isolated from HS-5, an immortalized stromal cell line, promoted the proliferation and 5-azacytidine (AZA) resistance of SKM-1 cells.

View Article and Find Full Text PDF

Botanical Nanovesicles Boost Mesenchymal Stem Cell Therapy: Next-Gen Advanced Therapy Medicinal Products for Spinal Cord Injury.

Tissue Eng Part B Rev

September 2025

Department of Pharmaceutics School of Pharmacy, Centre for Nano Drug/Gene Delivery and Tissue Engineering, Jiangsu University, Zhenjiang, People's Republic of China.

The poor prognosis constitutes a significant difficulty for spinal cord injury (SCI) individuals. Although mesenchymal stem cells (MSCs) hold promises as advanced therapy medicinal products (ATMPs) for SCI patients, challenges such as Good Manufacturing Practice-compliant manufacturing, cellular senescence, and limited therapeutic efficacy continue to hinder their clinical translation. Recent advances have identified botanical nanovesicles (BNs) as potent bioactive mediators capable of "priming" MSCs to self-rejuvenate, augment paracrine effect, and establish inflammatory tolerance.

View Article and Find Full Text PDF

Deciphering the molecular landscape of acute myeloid leukemia initiation and relapse: a systems biology approach.

Med Oncol

September 2025

Division of Hematology and Blood Bank, Department of Medical Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.

Acute Myeloid Leukemia (AML) patient-derived Mesenchymal Stem Cells (MSCs) behave differently than normal ones, creating a more protective environment for leukemia cells, making relapse harder to prevent. This study aimed to identify prognostic biomarkers and elucidate relevant biological pathways in AML by leveraging microarray data and advanced bioinformatics techniques. We retrieved the GSE122917 dataset from the NCBI Gene Expression Omnibus and performed differential expression analysis (DEA) within R Studio to identify differentially expressed genes (DEGs) among healthy donors, newly diagnosed AML patients, and relapsed AML patients.

View Article and Find Full Text PDF

Background: Several studies have suggested that adult human dermal fibroblasts (HDFa) may be a potential alternative source to mesenchymal stem cells for cell therapies. This study aims to characterize HDFa, adipose-derived stem cells (ADMSCs) and dental pulp stem cells (DPSCs) to investigate their proliferation, differentiation potential, mitochondrial respiration, and metabolomic profile. We identified molecules and characteristics that would differentiate MSCs from different sources or confirm their uniformity.

View Article and Find Full Text PDF